Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)
Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –
Acadia Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Acadia Pharmaceuticals's pe ratio was 8.3× on Nov 11, 2026, against 16.2× a year earlier. Over the last 3 years it ranged from 3.9× to 92.1×, with a median of 11.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.3× | −8.9 |
| 2025 | Dec 31, 2025 | 17.2× | −6.3 |
| 2024 | Dec 31, 2024 | 23.5× | +16.7 |
| 2012 | Jan 31, 2012 | 6.8× | +1.9 |
| 2011 | Dec 30, 2011 | 4.9× | – |
See a number that looks wrong?